Investor Relations
| Form | Description | Date | Format |
|---|---|---|---|
| SCHEDULE 13G/A | SCHEDULE 13G/A | Feb 17, 2026 |  Open SCHEDULE 13G/A in HTML. Open SCHEDULE 13G/A in DOC file. Open SCHEDULE 13G/A in PDF file. Open SCHEDULE 13G/A in XLS file. |
| SCHEDULE 13G/A | SCHEDULE 13G/A | Feb 10, 2026 | Open SCHEDULE 13G/A in HTML.Open SCHEDULE 13G/A in DOC file.Open SCHEDULE 13G/A in PDF file.Open SCHEDULE 13G/A in XLS file. |
Chemomab is developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from five clinical trials of nebokitug. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is preparing for potential initiation of a nebokitug Phase 3 trial in PSC. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND.
© Copyright 2025 Chemomab Therapeutics Ltd. All rights reserved. Privacy Policy. Terms of Use. Cookie policy.
Site Design by Michael Kulwiec DesignLab.
Site Design by Michael Kulwiec DesignLab.